ATC Group: C10AA05 Atorvastatin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10AA05 in the ATC hierarchy

Level
Code
Title
1
Cardiovascular system
2
Lipid modifying agents
3
Lipid modifying agents, plain
4
HMG CoA reductase inhibitors
5
C10AA05
Atorvastatin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
20 mg

Active ingredients in C10AA05

Active Ingredient
Description

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Medicines in this ATC group

Drug
Countries

Lithuania

South Africa

South Africa

South Africa

Cyprus

South Africa

Estonia Lithuania

South Africa

Brazil

Hong Kong

Singapore

Estonia

Singapore

Finland

Estonia Lithuania

Estonia Germany Hong Kong Italy Lithuania ...

Ecuador

Hong Kong

Hong Kong

Singapore

Australia

Brazil Poland

Tunisia

Singapore

Hong Kong

Ecuador

Poland

Singapore

Ecuador

Singapore

Hong Kong

Hong Kong

South Africa

South Africa

Hong Kong

South Africa

Singapore

Ecuador

South Africa

Singapore

South Africa

Hong Kong

Cyprus Poland

Tunisia

Poland

Hong Kong

South Africa

Hong Kong

Hong Kong

Hong Kong

Hong Kong

South Africa

Finland Hong Kong

Australia Brazil Canada Cyprus Ecuador ...

Hong Kong

Hong Kong

Ecuador

South Africa

Hong Kong

Ecuador

South Africa

Estonia Lithuania

Australia New Zealand

Lithuania

Finland

Hong Kong

Ecuador

Austria Estonia Germany Lithuania Poland ...

Ecuador Poland

Hong Kong

France Tunisia

Cyprus Estonia Lithuania Poland

Poland Singapore

Lithuania

Australia

Hong Kong Singapore

Australia

Estonia Poland Singapore

South Africa

Hong Kong

Brazil Ecuador

South Africa

Hong Kong

Hong Kong

New Zealand Spain

Related product monographs

Title
Type
Country
Medication Package Insert (MPI)
ZA
Summary of Product Characteristics (SPC)
CY
Medication Package Insert (MPI)
ZA
Medication Package Insert (MPI)
ZA
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK